AVROBIO to Present at Two Upcoming Investor Conferences in March

Rhea-AI Summary

AVROBIO, a leading clinical-stage gene therapy company, has announced its participation in two significant investor conferences. The Cowen 42nd Annual Health Care Conference will feature a panel on orphan CNS on March 8, 2022, at 2:10 p.m. ET, followed by a presentation at the Barclays Global Healthcare Conference on March 15, 2022, at 4:20 p.m. ET. Live webcasts will be available on the AVROBIO website. The company aims to deliver personalized gene therapy to treat genetic diseases, leveraging its plato® gene therapy platform.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:

Cowen 42^nd Annual Health Care Conference
Panel: Orphan CNS
Date: Tuesday, Mar. 8, 2022
Time: 2:10 p.m. ET

Barclays Global Healthcare Conference
Date: Tuesday, Mar. 15, 2022
Time: 4:20 p.m. ET

A live webcast of the panel at the Cowen 42^nd Annual Health Care Conference and presentation at Barclays Global Healthcare Conference will be available on the investors section of the AVROBIO website. After the live webcast, a replay of the event will remain available on the AVROBIO website for approximately 30 days.

About AVROBIO
Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt and/or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. AVROBIO’s pipeline is powered by our industry-leading plato^® gene therapy platform, our foundation designed to deliver gene therapy worldwide. It includes clinical programs in cystinosis and Gaucher disease type 1, as well as preclinical programs in Gaucher disease type 3, Hunter syndrome and Pompe disease. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statement
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective product candidates, including the implementation of the plato^® platform in our clinical trials and gene therapy programs and its potential impact on our commercialization activities. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato^® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005372/en/

Investor:

Christopher F. Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com

Media:

Kit Rodophele

Ten Bridge Communications

617-999-9620

krodophele@tenbridgecommunications.com

Source: AVROBIO

FAQ

What conferences is AVROBIO participating in March 2022?

AVROBIO will participate in the Cowen 42nd Annual Health Care Conference on March 8, 2022, and the Barclays Global Healthcare Conference on March 15, 2022.

When is the Cowen Health Care Conference panel scheduled?

The Cowen 42nd Annual Health Care Conference panel is scheduled for March 8, 2022, at 2:10 p.m. ET.

What time does AVROBIO's presentation at the Barclays Conference start?

AVROBIO's presentation at the Barclays Global Healthcare Conference starts at 4:20 p.m. ET on March 15, 2022.

Where can I watch AVROBIO's conference presentations?

You can watch AVROBIO's conference presentations live on the AVROBIO website, where replays will be available for approximately 30 days after the events.

What is AVROBIO's focus in gene therapy?

AVROBIO focuses on delivering personalized gene therapy to prevent, halt, or reverse genetic diseases, utilizing its plato® gene therapy platform.